Late-stage pharmaceutical company Achieve Life Sciences Inc (Nasdaq:ACHV) announced on Wednesday that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to cytisinicline for nicotine e-cigarette, or vaping, cessation.
This designation is based on results from the Phase 2 ORCA-V1 trial, which showed that cytisinicline more than doubled the odds of quitting e-cigarettes compared to placebo.
Cytisinicline has the potential to be the first FDA-approved medication for nicotine vaping cessation.
Breakthrough Therapy Designation will expedite the development and review of cytisinicline. Achieve plans to hold an End-of-Phase 2 meeting with the FDA before the end of the year.
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
Syndax Pharmaceuticals grants share purchase inducement awards to six new employees
Hippo Pharmacy launches fast, free delivery on orders over USD150
Polarean Imaging expands reach with Taiwanese distribution deal
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
CHMP recommends EU approval of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan
Renalys Pharma completes patient enrolment for Phase III clinical trial of sparsentan
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
Roche's blood test measuring Lp(a) in molar units receives US FDA 510(k) approval
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
HeartBeam submits FDA 510(k) application for groundbreaking 12-lead ECG synthesis software
FDA grants Vicore Pharma Fast Track Designation for buloxibutid in idiopathic pulmonary fibrosis
FDA accepts Saol Therapeutics' SL1009 New Drug Application for Priority Review